SILVER




GenIbet Biopharmaceuticals
GenIbet Biopharmaceuticals is a GMP biopharmaceutical CDMO offering highly specialized GMP manufacturing and development services. GenIbet core activity is the manufacture and supply of starting materials and Investigational Medicinal Products for use in early-stage drug development, pre-clinical studies and GMP manufacturing for clinical trials.
GenIbet expertise spans over a broad spectra of Biopharmaceuticals development, including recombinant proteins, Vaccines, RNA, Live Microbial Products and Cell and Gene Therapy products. GenIbet’s manufacturing portfolio includes a variety of mammalian, avian and insect cells, microorganisms and Viruses.
As of early 2022, GenIbet is part of Recipharm a leading CDMO, which is currently expanding its well-established capabilities on small molecules from preclinical-to-clinical and commercial approval to include new biological modalities such as viruses, viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Recipharm network on Biologics includes GenIbet, ArrantaBio and Vibalogics.